Interim Report from a Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor: Clinical Activity and Favorable Safety in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Franck Morschhauser, Gilles Salles, Pamela Mckay, Herve Tilly, Anna Schmitt, John Gerecitano, Peter Johnson, Steven Le Gouill, Michael Dickinson, Christophe Fruchart, Thierry Lamy, Aristeidis Chaidos, Wojciech Jurczak, Stephen Opat, John Radford, Pier Luigi Zinzani, Sarit Assouline, Guillaume Cartron, Alicia Clawson, Natasha Picazio Show all